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Abstract
Telomerase is a ribonucleoprotein complex involved in the maintenance of telomeres, a protective structure at the distal
ends of chromosomes. The enzyme complex contains two main components, telomerase reverse transcriptase (TERT), the
catalytic subunit, and telomerase RNA (TR), which serves as a template for the addition of telomeric repeats (TTAGGG)n.
Marek’s disease virus (MDV), an oncogenic herpesvirus inducing fatal lymphoma in chickens, encodes a TR homologue, viral
TR (vTR), which significantly contributes to MDV-induced lymphomagenesis. As recent studies have suggested that TRs
possess functions independently of telomerase activity, we investigated if the tumor-promoting properties of MDV vTR are
dependent on formation of a functional telomerase complex. The P6.1 stem-loop of TR is known to mediate TR-TERT
complex formation and we show here that interaction of vTR with TERT and, consequently, telomerase activity was
efficiently abrogated by the disruption of the vTR P6.1 stem-loop (P6.1mut). Recombinant MDV carrying the P6.1mut stem-
loop mutation were generated and tested for their behavior in the natural host in vivo. In contrast to viruses lacking vTR, all
animals infected with the P6.1mut viruses developed MDV-induced lymphomas, but onset of tumor formation was
significantly delayed. P6.1mut viruses induced enhanced metastasis, indicating functionality of non-complexed vTR in tumor
dissemination. We discovered that RPL22, a cellular factor involved in T-cell development and virus-induced transformation,
directly interacts with wild-type and mutant vTR and is, consequently, relocalized to the nucleoplasm. Our study provides
the first evidence that expression of TR, in this case encoded by a herpesvirus, is pro-oncogenic in the absence of
telomerase activity.
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Introduction
Telomerase is a multi-component ribonucleoprotein complex.
One of its main functions is the maintenance of telomeres, a
protective structure at the termini of linear chromosomes. The
telomerase complex consists of two essential core components,
telomerase reverse transcriptase (TERT) and telomerase RNA
(TR), which serves as a template for the catalytically active subunit
in the elongation of telomeric repeats (TTAGGG)n at the end of
chromosomes [1]. TR contains four structural domains, which are
highly conserved regions (CR) in all vertebrates: I) the pseudoknot
(core) domain, containing the template sequence (CR1); II) the H/
ACA box and III) the conserved region (CR) 7 domain, both of
which are essential for TR stability and localization; IV) the CR4-
CR5 domain, which is required for efficient TR-TERT complex
formation, hence telomerase activity and processivity [2,3]. An
essential structure within the CR4-CR5 domain is the P6.1 stem-
loop. Base pairing of the P6.1 stem is completely conserved in all
vertebrates. Disruption of the base paring of the P6.1 stem was
shown to interfere with proper TR-TERT interaction and resulted
in absence of telomerase activity in vitro and in vivo [3–5]. In
addition, the P6.1 stem-loop was shown to interact with conserved
sequences of the template region CR1, which also plays a critical
role in the catalytic activity of the telomerase complex [5].
Telomerase activity is tightly regulated and varies amongst cell
types. While it is commonly up-regulated in germ-line, stem and
cancer cells, it is absent in most somatic cells [6]. The absence of
telomerase activity often leads to progressive telomere shortening,
known to initiate cellular senescence and irreversible cell cycle
arrest. Several tumor-inducing viruses have evolved strategies to
evade and subvert this mechanism of cellular senescence, mainly
via the up-regulation of TERT, which was shown to be the
limiting factor of telomerase activity in some organisms, such as
the human and the chicken [7,8]. It has been suggested that up-
regulation of TERT expression and provision of more active
telomerase increases the proliferative potential of persistently
infected cells, which in turn might be beneficial to accumulate
genetic alterations and transformation after infection [8].
One of the most remarkable viruses with respect to the
efficiency of the induction of fatal tumors is Marek’s disease virus
(MDV), a lymphotropic alphaherpesvirus, that causes Marek’s
disease (MD) in chickens, characterized by neurological disorders,
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[9]. The rapid onset of MD-induced lymphomas, as early as 2
weeks post-infection, and high tumor-induced mortality (90–100%
in susceptible animals), suggests a direct involvement of virus-
encoded oncogenes in the process. The major MDV oncogene,
meq, encodes a basic leucine zipper (bZIP) transcription factor (TF)
that was shown to interact with Rb, cdk2 and p53, proteins
involved in cell-cycle control, and several cellular TFs including c-
Jun, c-Fos and c-Myc, an oncogene known to regulate TERT
expression [10,11]. In addition, and as a unique feature, the MDV
genome harbors two copies of its own TR subunit, termed viral
TR (vTR), that shares 88% sequence identity with chicken TR
(chTR), contains all four conserved structural TR domains, and
was likely acquired from the chicken genome [2]. The 180-kbp
linear, double-stranded DNA genome of MDV consists of a long
(L) and short (S) unique region (UL and US) flanked by terminal
(TRL or TRS) and internal (IRL or IRS) inverted repeats. Both
vTR copies are located in the repeats flanking the UL,T R L and
IRL. Besides the presence of vTR in the TRL and IRL, MDV also
contains two sets of tandem repeats in very close proximity to the
genomic termini that represent perfect telomeres [12].
vTR is expressed during both lytic and latent MDV infection. It
is functionally active and was shown to more efficiently induce
telomerase activity in vitro when compared to its cellular
homologue, chTR [13,14]. Although dispensable for lytic
replication in vitro and in vivo, vTR is required for efficient
MDV-induced tumorigenesis, as MDV mutants lacking both
copies of vTR were severely impaired in lymphoma formation and
dissemination [14].
Recent reports suggest that both TERT and TR may also have
roles in tumorigenesis aside from their role in the maintenance of
telomere length in rapidly dividing cells [7,15,16]. For example,
human TR has been shown to restrain activity of ATR, a factor in
the DNA damage response pathway, in a telomerase-independent
fashion allowing the survival of cells after cellular stress such as UV
radiation [17]. Furthermore, knockdown of TR in human cancer
cells induced rapid changes in the global gene expression profiles
that were independent of telomere maintenance and DNA
damage responses. Induced changes in expression levels included
genes involved in cell cycle progression (Cyclin G2 and Cdc27)
and adhesion (integrin aV), that may have an effect on MDV
pathogenesis and tumorigenesis as well [15]. Similarly, expression
of vTR in the chicken fibroblast DF-1 cell line that does not
exhibit telomerase activity, induced a 2-fold increase of integrin
aV expression, suggesting a telomerase-independent function for
vTR [14,15,18].
One potential interaction partner of vTR is ribosomal protein
L22 (RPL22), previously shown to interact with human TR [19].
Besides associating with ribosomes, RPL22 is also involved in the
development of T-cells [20,21], the target of MDV transforma-
tion. Epstein-Barr virus (EBV), a herpesvirus that shares many
pathobiological similarities with MDV, encodes two small RNAs,
termed EBER-1 and EBER-2, that contribute to tumor formation
and are highly abundant in latently infected cells [22]. EBER-1
was shown to interact with RPL22 and the interaction resulted in
relocalization of RPL22 from the nucleolus to the nucleoplasm.
The interaction of EBER-1with RPL22 is associated with
enhanced potential for cellular proliferation [22,23].
In order to elucidate whether MDV vTR has functions that are
independent of telomere maintenance and its presence in the
telomerase complex, we mutated the P6.1 stem-loop present in
CR4-CR5 of MDV-encoded vTR. The mutation was shown to
efficiently abrogate vTR-mediated telomerase activity in vitro. In
vivo studies analyzing MD incidence, tumor development and
dissemination confirmed that vTR serves functions that are both
dependent and independent of the formation of an active
telomerase complex. In addition, we identified RPL22 as an
interaction partner of vTR and show that it is relocalized upon
vTR expression. To our knowledge, the data presented here
provide the first in vivo evidence that a TR executes functions
important for tumor formation that are independent of telomerase
activity and likely depend on the alternate usage of RPL22 in the
transformation process.
Results/Discussion
vTR P6.1 stem-loop mutation efficiently disrupts
telomerase activity
To ensure that the disruption of the vTR P6.1 stem-loop, as
previously shown for cellular TRs, efficiently abrogates vTR-
TERT interaction and consequently telomerase activity, we
performed gel-based telomere repeat amplification protocol
(TRAP) assays. Base pairing of the P6.1 stem-loop was disrupted
by mutating base pairs (bp) 295–298 of vTR from 59-AGAG-39 to
59-UCUC-39 (Fig. 1A). In order to confirm the absence of
telomerase activity via TRAP assay, in vitro transcription was used
to generate various vTR’s (Fig. 1B) that were used in the TRAP
assays: wild- type (wt) vTR, vTR containing the P6.1 mutation
(Fig. 1A), or, as a negative control, vTR containing a mutation in
the template sequence (AU5) resulting in the addition of
(TATATA)n repeats that are not amplified in the TRAP assay.
Functional chTERT protein was obtained by in vitro transcription
of a synthetic cDNA followed by translation using a rabbit
reticulocyte lysate system (Fig. 1C). In order to reconstitute the
telomerase complex, chTERT was incubated with vTR variants or
actin control RNA and telomerase activity analyzed by TRAP
assays. While TRAP products were readily detected with wt vTR
confirming earlier results [13], telomerase activity was undetect-
able when vTR with the P6.1 mutation was used, as was evident
from the absence of TRAP products in reactions containing
Author Summary
The enzyme complex telomerase, with its two main
components telomerase reverse transcriptase and telome-
rase RNA, plays an important role in telomere mainte-
nance. Perturbation of telomere length regulation can
ultimately result in cellular senescence (telomere shorten-
ing) and is also observed in tumor cells (increased
telomere maintenance). Recent studies suggest telome-
rase RNAs can function independently of the telomerase
complex and promote tumor development independently
of telomere maintenance. Here we demonstrate that vTR, a
herpesvirus-encoded telomerase RNA, serves two distinct
functions in MDV-induced tumor formation. vTR has its
first function early after infection, when it is part of the
telomerase complex and contributes to the survival of
rapidly dividing transformed cells. The second function of
vTR is independent of telomerase action and essential for
formation of solid lymphomas and metastasis. This latter
function is likely a consequence of vTR-mediated gene
regulation that is at least in part controlled by its
interaction with and relocalization of RPL22, a cellular
factor involved in T-cell development and virus-induced
transformation. Taken together, our study demonstrates
that telomerase RNA encoded by a herpesvirus is directly
involved in tumor formation in vivo in a fashion that is
largely independent of its function within an active
telomerase complex.
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(AU5) or negative control RNA to the TRAP reaction did not
result in telomere elongation (Fig. 1D). Although clearly
detectable, few TRAP products were obtained with the vTR-
TERT combination. The relatively low activity of reconstituted
vTR-TERT compared with the positive control TR could be due
to the low TERT levels generated by in vitro transcription/
translation, the lack of accessory telomerase factors, or a high
protein content of the reticulocyte lysates known to reduce TRAP
product generation [24].Our results clearly demonstrated, how-
ever, that the introduced mutation within the vTR P6.1 stem-loop
completely abrogates the formation of an active telomerase
complex.
Construction of MDV bacterial artificial chromosome
(BAC) mutants
To determine whether the established tumor-promoting
function of vTR is dependent on the formation of an enzymatically
active telomerase complex, we manipulated the P6.1 stem-loop in
pRB-1B, an infectious BAC clone of the highly oncogenic RB-1B
MDV strain (Fig. 2A) [25]. Base pairing of the P6.1 stem-loop was
disrupted by mutating base pairs (bp) 295–298 of vTR, as
described above, via two-step Red-mediated mutagenesis [26]
(Fig. 1A). Two rounds of identical mutagenesis allowed the desired
alteration of both copies of the diploid vTR gene within the MDV
genome, and the resulting mutant infectious clone was termed
pP6.1mut. In addition, a revertant BAC clone (pP6.1rev) was
generated in which the original sequence was restored in both
alleles. All clones were confirmed by PCR, DNA sequencing and
multiple restriction fragment length polymorphism analyses
(RFLP) to ensure the integrity of the genome (Fig. 2B). In order
to confirm that the mutation did not revert during any of the
experimental procedures, DNA of stock viruses used for infection
of the animals and viral DNA obtained from tumor cells were
analyzed by nucleotide sequencing, which demonstrated that the
vTR mutants were genetically stable throughout the experiments.
vTR-TERT interaction and telomerase activity are
dispensable for efficient lytic viral replication in vitro and
in vivo
In order to investigate the effect of the P6.1 stem-loop mutation
on virus replication in vitro, wt pRB-1B, pP6.1mut and pP6.1rev
BACs were transfected into chicken embryo cells (CEC) resulting
in the reconstitution of recombinant viruses termed vRB-1B,
vP6.1mut and vP6.1rev. Multi-step growth kinetics revealed that
replication of vP6.1mut was unaffected in vitro when compared to
that of wt vRB-1B or vP6.1rev (Fig. 3A). In addition, mutation of
the P6.1 stem-loop had no effect on the plaque sizes induced by
the vP6.1 virus mutant (Fig. 3B). These findings were consistent
Figure 1. Effect of the P6.1 mutation on telomerase activity. A)
Schematic of the CR4–CR5 domain including a detailed representation
of the P6.1 stem-loop. Structure of wild-type P6.1 (left) and mutant P6.1
stem-loop (P6.1 mut) (right) is shown. Nucleotide changes of the wt
P6.1 stem-loop (blue) are shown in red. B) In vitro transcribed b-actin
control RNA, wt vTR RNA, vTR containing the P6.1 mutation (P6.1) or a
mutation in the template sequence (AU5) was analyzed on a 2%
denaturing agarose-formaldehyde gel. Expected vTR size is indicated by
the black arrow. C) Chicken TERT-His was translated in vitro using rabbit
reticulocyte lysates and subsequently analyzed via western blotting
using an anti-5x-His antibody. The expected size of TERT-His is indicated
with the black arrow. D) Telomerase activity of the in vitro transcribed
vTR variants was analyzed using gel based TRAP-assays. TRAP products
and the internal control (IC) are indicated. The results shown are
representative for three independent experiments showing similar
results.
doi:10.1371/journal.ppat.1001073.g001
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PLoS Pathogens | www.plospathogens.org 3 August 2010 | Volume 6 | Issue 8 | e1001073Figure 2. MDV genome organization and P6.1 stem-loop mutation. A) Schematic representation of the MDV genome including the unique-
short and -long regions (US,U L) flanked by terminal and internal repeat regions (TRS,T R L,I R S,I R L). The focus on the vTR containing regions shows the
telomeric repeat region present in the MDV genome (left), vTR including its conserved regions (CR) 1–8, and the three exons of the neighboring vIL-8
gene (right). B) Restriction fragment length polymorphism analyses of pRB-1B (lane 2, 6, 10), vP6.1mut (lane 3, 7, 11) and vP6.1rev (lane 4, 8, 12) using
the indicated restriction enzymes. Lane 1, 5, and 9 show the 1 kb plus ladder (Invitrogen) ranging from 2 kbp (lowest band) till 12 kbp (highest band)
in exact 1 kbp increments.
doi:10.1371/journal.ppat.1001073.g002
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vTR is dispensable for lytic virus growth in vitro [14].
Since efficient lytic replication in vivo is considered a prerequisite
for efficient lymphomagenesis, we analyzed the replicative
potential of the various mutant viruses in the natural host. We
infected 1-day-old chickens and monitored virus levels by qPCR
using DNA isolated from whole blood obtained by wing vein
puncture until 28 days post infection (dpi). MDV is present in
peripheral blood mononuclear cells (PBMC) and qPCR analyses
showed that vP6.1mut replicated in those cells to levels that were
comparable to those of wt vRB-1B or vP6.1rev (Fig. 4A). The
results were again consistent with published data on the lytic
replication of vTR deficient viruses, which were shown to be fully
capable of robust lytic replication [14]. The observed dispensabil-
ity for lytic replication of vTR-TERT interaction and vTR-
mediated telomerase activity in general can be explained by the
fact that the initial virus production in chicken B and T cells does
not require long-term survival of the host cell or host cell
proliferation. Survival of the latently infected host cell is, however,
a prerequisite for, or consequence of transformation and tumor
formation in general. From the results of the experiments on lytic
replication of the P6.1mut viruses we concluded that viruses
containing the P6.1 stem-loop mutation are capable of efficient
replication in cultured cells in vitro as well as in the target cells in
vivo. Therefore, vTR-TERT interaction mediated by the P6.1
stem-loop and, therefore, telomerase activity is dispensable for
MDV replication in vivo.
Onset of MDV-induced lymphoma is delayed in the
absence of vTR-TERT interaction and vTR-mediated
telomerase activity
We have previously shown that MD lymphoma formation was
significantly reduced in the absence of vTR [14]. To address
whether the observed reduction is dependent on the interaction of
vTR with TERT, we performed two independent animal
Figure 3. Growth properties of viruses containing the P6.1
stem-loop mutation. A) Multi-step growth kinetics of wt vRB-1B,
vP6.1mut and vP6.1rev were performed in triplicates and are shown as
means with standard deviations (error bars). B) Plaque size assay.
Results are shown for the three recombinant viruses as the relative
mean plaque area in percent of 100 randomly selected plaques induced
by each of the viruses with the corresponding standard deviations
(error bars).
doi:10.1371/journal.ppat.1001073.g003
Figure 4. P6.1 stem-loop mutation does not affect lytic
replication in vivo, but delays MD incidence. A) qPCR analysis of
the viral ICP4 gene and the host iNOS gene. Blood samples were taken
at 4, 7, 10, 14, 21, and 28 dpi and total DNA was extracted. Mean MDV
genome copies/10
6 blood cells of eight infected chickens per group as
determined by qPCR analysis are shown with standard deviations (error
bars). B) 1
st animal experiment: MD incidence in percent in chickens
infected with vRB-1B (n=5), vP6.1mut (n=10) and vP6.1rev (n=8)
during the indicated time period C) 2
nd animal experiment: MD
incidence in percent of vP6.1mut (n=22) and vP6.1rev (n=20) during
the indicated time period. The time to develop MD in 50% of the
inoculated animals (MD50) is indicated (dashed line) and was
significantly increased in the P6.1mut group (p=0.0012).
doi:10.1371/journal.ppat.1001073.g004
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virus-induced lymphoma in chickens infected with vRB-1B,
vP6.1mut or P6.1rev. In a first animal experiment, we established
that abrogation of vTR-mediated telomerase activity markedly
delayed the onset of MD lymphomas (Fig. 4B). We observed that
the time until development of tumors and occurrence of MD in
50% of the infected animals (MD50) was increased from 36 dpi in
vRB-1B-infected chickens (n=5) and 32 dpi in vP6.1rev-infected
animals (n=8) up to 46 dpi in vP6.1mut-infected birds (n=10).
In a second animal experiment, the clinician examining
inoculated chickens was blinded to eliminate subjectivity. In
agreement with the results of the first animal experiment, MD50
was significantly delayed in vP6.1mut infected chickens (49 dpi,
n=22) when compared to vP6.1rev expressing wt vTR (32 dpi,
n=20) (p=0.0012). We hypothesize that the observed delay in the
development of lymphomas is caused by curtailing telomerase
activity mediated by vTR and, consequently, the absence of
enhanced telomere maintenance. Such enhanced telomere
maintenance, which was shown in MDV-infected animals [27]
and is thought to play an important role for the survival of rapidly
dividing MDV-transformed cells early in the transformation
process, is probably mediated mainly by an interaction between
vTR and cellular chTERT. In the absence of the P6.1 stem-loop,
the interaction can no longer occur, and, therefore, the pool of
transformed cancer stem cells surviving the initial crisis may be
reduced.
It was notable, however, that, in contrast to viruses lacking vTR
[14], all animals infected with v6.1mut succumbed to MD before
termination of the experiment, indicating that vTR has functions
independent of the formation of an active telomerase complex.
From the results of the animal experiments we conclude that the
rapid onset of MD observed in chickens infected with wt MDV
(vRB-1B) or the vP6.1rev virus is dependent on telomerase activity
that involves vTR-chTERT interaction. Lymphoma formation,
however, and fatal disease outcome are efficient even in the
absence of enzymatically active telomerase.
vTR-TERT interaction is not required for efficient tumor
dissemination
MDV-induced tumor formation and metastasis were previously
shown be significantly reduced in the absence of vTR [14]. In
addition, our earlier findings of integrin aV up-regulation
mediated by vTR alone suggested that malignant lymphoma
dissemination may be a result of the action of vTR that is
independent of vTR-TERT interaction [14]. To address whether
animals infected with the P6.1mut virus, where vTR-TERT
complex formation is absent and, hence, more non-complexed
vTR is available, would corroborate these earlier findings. We
enumerated the gross lesions in infected birds during necropsies on
animals that had succumbed to infection. Consistent with our
earlier results and the hypothesis that lymphomagenesis and
metastasis could be largely determined by vTR action alone,
disruption of the P6.1 stem-loop led to a significant increase in the
number of solid lymphomas in chickens infected with the
vP6.1mut virus when compared to vP6.1rev-infected chickens
(p=0.0016). All vP6.1mut-infected animals developed gross
tumors in at least three organs (Fig. 5A). Furthermore, the
average number of organs with solid lymphomas was mildly albeit
significantly increased from 3.1 in vP6.1rev to 4.0 in vP6.1mut
(p=0.0381; Fig. 5B). We concluded, therefore, that efficient tumor
dissemination observed in vP6.1mut-infected animals supported
the results of a previous study suggesting that vTR is involved in
increased lymphoma dissemination and metastasis [14].
vTR does not contribute to telomerase activity in MDV
transformed tumor cells
In order to address whether telomerase activity was affected in
tumor cells derived from vP6.1mut-infected animals, we per-
formed quantitative CY5 gel-based TRAP assays as described by
Herbert and coworkers [28]. The experiment showed that
telomerase activity was not affected in primary tumor cells derived
from vP6.1mut-infected animals when compared to tumor cells
recovered from animals infected with parental vRB-1B virus,
suggesting that endogenous TR in transformed T-cells can
compensate for the telomerase activity mediated by vTR. In
addition, we analyzed established, clonal LCLs derived from
animals infected with vRB-1B or virus containing the P6.1 stem-
loop mutation. vP6.1mut-derived cell lines exhibited telomerase
activity comparable to those transformed with wild-type vRB-1B.
To address whether vTR contributes to telomerase activity during
MDV transformation in vitro, we performed TRAP assays using
CU91, a retrovirus-transformed T-cell line obtained from chickens
with the same genetic background (B
19B
19) as the animals from
which cell lines after infection with vRB-1B or vP6.1mut were
derived. Similarly, the CU210 cell line was used, which was
generated by superinfection of CU91 with MDV strain RB-1B
[33]. Latent MDV infection in CU210 and, hence, vTR
expression, did not increase telomerase activity when compared
to the parental CU91 cell line, which showed higher telomerase
levels when compared to the MDV-derived cell lines. The high
telomerase activity of MSB-1, an MDV-transformed and highly
passaged LCL, suggested that such serial passage might select for
increased telomerase activity that likely contributes to a profound
transformation phenotype that is reflected by very robust
proliferation observed for MSB-1 [29]. Taken together, our data
suggested that vTR does not contribute to telomerase activity in
MDV-transformed tumor cells, which further lends support to the
hypothesis of telomerase-independent functions of vTR in the
development and dissemination of lymphoma.
vTR and vTR P6.1 efficiently interact with RPL22
As previously reported, EBV transformation mediated by
EBER-1 is dependent on its interaction with RPL22 [22]. In
order to determine if wild-type and/or mutant P6.1 vTR interact
with RPL22, we performed biotin-RNA pull-down assays. vTR,
vTR P6.1, chTR and EBER-1 were found to precipitate RPL22,
while biotin-labeled b-actin control RNA did not (Fig. 5C). EBER-
1 showed the strongest interaction that was 5.1-fold stronger than
that determined for vTR (Fig. 5D), potentially because it contains
three independent RPL22 binding sites [30]. The interaction of
chTR with RPL22 was reduced by 2.0-fold, indicating that
cellular TR does not interact as strongly as that encoded by MDV.
vTR P6.1 showed a 1.9-fold increase in precipitated RPL22 when
compared to wild-type vTR. This apparently enhanced interaction
could be caused by a conformational change of the P6 stem-loop
structure, that exhibits high similarity to the EBER-1 stem-loop 3
that is known to interact with RPL22 [30]. In addition, the
abrogation of vTR-TERT interaction in MDV infected cells could
increase the amount of free vTR available for RPL22 interaction,
which may provide an explanation for the increased number of
solid tumors found in vP6.1mut infected animals.
vTR expression affects RPL22 localization
Finally, to address whether vTR expression has an affect on the
localization of RPL22, we determined RPL22 localization by
confocal microscopy in vTR-transfected cells. HeLa cells were co-
transfected with an expression plasmid encoding RPL22 that is C-
Herpesvirus Telomerase RNA and Lymphoma Formation
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expressing EBER-1, vTR, P6.1mut or chTR. In cells transfected
with RPL22-mRFP alone or together with empty vector, RPL22-
mRFP localized almost exclusively to the nucleolus as described
previously [31]. As shown in previous reports, EBER-1 expression
induced relocalization of RPL22; however, RPL22 was not
completely absent from the nucleoli, which could possibly be
attributed to lower amounts of EBER-1 plasmid DNA used here
when compared to earlier reports (Fig. 6C). A relocalization of
RPL22 quite similar to that following EBER-1 expression was also
detected for vTR, P6.1mut and chTR, suggesting that over-
expression of viral as well as cellular TR affects RPL22 subcellular
distribution (Fig. 6C–E). Cells with a nucleolar localization of
RPL22 were quantified to confirm that the relocalization is a
general and not isolated event. As in cells transfected with EBER-
1, the number of cells with nucleolar RPL22 localization was
clearly reduced after co-expression of vTR, P6.1mut or chTR.
Under the conditions used here, efficiency of relocalization of
RPL22 was comparable between EBER-1 and the vTR and chTR
constructs (Fig. 6), which may suggest that EBER-1 and vTR serve
similar purposes in the process of transformation of human and
chicken lymphocytes.
Figure 5. vTR-TERT interaction is not required for efficient tumor dissemination or for telomerase activity in tumor cells. A)
Dissemination pattern of vP6.1mut (22 chickens) and vP6.1rev (20 chickens) for in vivo experiment 2. Moribund chickens were euthanized, necropsied
and evaluated for lymphoma dissemination. Results are shown as percentage of animals with 1–2, 3–4 or 5–6 organs containing lymphomatous
lesions. B) Mean number of tumors per animal with standard deviations. The mean number was significantly increased in the P6.1mut group
indicated by the asterisk (p=0.0381). C–D) Telomerase activity in primary tumor cells (C) and clonal LCLs (D) derived from vRB-1B or vP6.1mut
infected animals as indicated using the Cy5 gel based TRAP-assay. TRAP products and the internal control (IC) are indicated. E–F) Quantification of
telomerase activity in primary tumor cells (E) and established LCLs (F). The data are shown as mean telomerase activity relative to the positive control
in three (E) or two (F) independent experiments.
doi:10.1371/journal.ppat.1001073.g005
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In this report, we demonstrate that the herpesvirus telomerase
RNA, vTR, has at least two functions in virus-induced
lymphomagenesis. One of its functions is dependent on vTR-
TERT interaction, while the other is independent of the
formation of an active telomerase complex. The rapid onset of
lymphoma formation seems dependent on vTR-mediated telo-
merase activity because a delay in the development of tumors was
observed when vTR-TERT interaction was abrogated. The
documented increase in telomerase activity mediated by the
presence of vTR in complex with TERT when compared to the
presence of cellular TR likely plays an important role in the initial
establishment and maintenance of MDV-transformed cells. It
may, therefore, facilitate the development of lymphomas by
increasing the pool of candidate tumor stem cells (Fig. 7).
Functions of vTR that are independent of telomerase activity,
however, are needed later in the process and influence homing of
tumor cells to various organs, seeding and metastasis. These
processes are likely a consequence of TR-mediated gene
regulation [15] and the interaction of vTR with RPL22 suggests
an alternative mechanism involved in transformation that may be
similar to that demonstrated for EBV EBER-1 (Fig. 7). In
conclusion, our study demonstrates that TR is directly involved in
tumor formation in vivo, in a fashion that is independent of its
function as an integral component of an active telomerase
complex.
Materials and Methods
Ethics statement
All animal work was conducted at Cornell University according
to national regulations. The animal care facilities and programs of
Cornell University meet the requirements of the law (89–544, 91–
579, 94–276) and NIH regulations on laboratory animals, and are
in compliancewiththe Animal Welfare Act, PL279. The College of
Veterinary Medicine at Cornell University is accredited by the
Association for Assessment and Accreditationof Laboratory Animal
Care. All experimental procedures were in compliance with
approval of Cornell University’s Institutional Animal Care and
Use Committee (IACUC, internal approval number: 2002-0085).
Cells and viruses
MDV transformed lymphoblastoid T cell lines (LCL) were
generated as described previously and cultivated in RPMI medium
1640 plus 10% FBS and 8% chicken serum at 41uCi na
humidified atmosphere of 5% CO2 [32,33]. The MSB-1 cell line
was kindly provided by Mark S. Parcells (University of Delaware,
Newark, DE) whereas the CU91 and CU210 [34] cell lines were
kindly provided by Karel A. Schat (Cornell University, Ithaca,
NY). CECs were prepared from specific-pathogen-free embryos
and maintained as described previously [35]. Recombinant viruses
were reconstituted in CECs by CaPO4 transfection of purified
BAC DNA as described previously [36,37]. The lox-P-flanked
Figure 6. vTR interacts with and affects localization of RPL22. A) Biotin-RNA pull-down assay. Precipitated RPL22 (upper panel), unbound
supernatant (middle panel), and RNA input control (lower panel) of indicated RNAs are shown. The figure is a representative of three independent
experiments yielding identical results. B) Quantification of three independent Biotin-RNA pull-down assays. Mean RPL22 quantities are shown relative
to vTR with standard deviations (error bars). C) RPL22 localization in HeLa cells transfected with pcDNA-RPL22-mRFP and empty vector (pCMS-EFGP),
vTR (pCMS-vTR), vTR P6.1mut (pCMS-vTR-P6.1mut), EBER-1 (pSG5-EBER-1) or chTR (pcDNA-chTR). Representative images of cells from three
independent experiments are shown. D) Quantification of nucleolar RPL22 localization in HeLa cells. At least 160 individual cells were evaluated for
each sample. Data are shown as mean percentages of circular RPL22 localization of three independent experiments with standard deviations (error
bars).
doi:10.1371/journal.ppat.1001073.g006
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cotransfection with a Cre recombinase expression vector
(pCAGGS-NLS/Cre) [36]. Removal of the mini-F sequences
was ensured by analyzing recombinant virus stocks by analytic
PCR as described previously [36]. Virus propagation as well as
determination of virus growth kinetics and plaque sizes were
performed as described previously [38].
Generation of mutant MDV
pP6.1mut and pP6.1rev were generated by two-step Red-
mediated recombination [26,36]. Primers used for the mutagenesis
are given in Table 1.
In vivo experiments
SPF P2a (MHC: B
19B
19) chickens were inoculated intra-
abdominally with 500 to 2,000 plaque-forming units at day 1 of
age and housed in isolation units. All experimental procedures
were conducted in compliance with approved Institutional Animal
Care and Use Committee (IACUC) protocols (internal approval
number: 2002-0085). Chickens were evaluated for symptoms of
MDV-induced disease on a daily basis and examined for gross
tumors when clinical symptoms were evident.
DNA extraction and qPCR assays
DNA was extracted from whole blood and MDV genomic
copies were determined by qPCR [39,40]. Briefly, MDV DNA
copy numbers were detected using primers and probe specific for
the ICP4 locus and normalization was achieved using chicken
inducible nitric oxide synthase (iNOS) genome copies.
Cloning of vTR variants, chTERT, chTR and RPL22
vTR was amplified from pRB-1B and subsequently cloned into
the PstI and XbaI sites of the pUC119 plasmid resulting in plasmid
pUC119-vTR. The T7 promoter was inserted at the 59 end of
vTR via a 59 overhang in the vTR-T7-for primer. vTR was also
cloned into the EcoRI and BamHI sites of the pCMS-EGFP
plasmid resulting in plasmid and pCMS-vTR. Mutation of the
template (AU5) and the P6.1 stem-loop was done based on
pUC119-vTR and pCMS-vTR by Phusion Site-Directed Muta-
genesis (Finnzymes Inc.) according to the supplier’s instructions
and resulting in pUC119-vTR-AU5, pUC119-vTR-P6.1 and
pCMS-vTR-P6.1 respectively. Chicken TERT (chTERT) was
obtained as a synthetic, codon-optimized sequence from Gen-
Script (Piscataway, NJ USA), PCR amplified including an
upstream Kozak sequence and inserted into pcDNA3.1/V5-His
TOPO (Invitrogen) containing a 59 T7 promoter, resulting in
plasmid pcDNA-chTERT-His. Chicken TR (chTR) and RPL22
was amplified from chicken DNA and inserted into pcDNA3.1/
V5-His TOPO, resulting in pcDNA-chTR and pcDNA-RPL22-
His. For the expression of fluorescently labeled RPL22, we
amplified mRFP from pmRFP-1 [41] and inserted it into the XhoI
site of pcDNA-RPL22-His resulting in pcDNA-RPL22-mRFP.
Oligonucleotides used for amplification are given in Table 1.
In vitro transcription
vTR variants, chTR, EBER-1, or b-actin were transcribed
using the Maxiscript T7 kit (Ambion) following the manufacturer’s
instructions where the linearized plasmids pUC119-vTR,
pUC119-vTR-AU5, pUC119-vTR-P6.1, cDNA-chTR, pSG5-
EBER-1 (a kind gift of Dr. Rona Scott, Louisiana State University
Health Science Center, Shreveport, LA) and pTRI-b-actin
(Ambion) served as templates. Biotin-labeled RNAs were gener-
ated using the biotin RNA labeling mix (Roche). chTERT and
RPL22 were transcribed via the mMESSAGE mMACHINE T7
Kit (Ambion) according to the supplier’s recommendation using
linearized pcDNA-chTERT-His or pcDNA-RPL22 as templates.
RNAs were purified via the RNeasy Kit (Qiagen), analyzed on a
Figure 7. Model of chTR and vTR during MDV infection with vP6.1mut. chTR (gray) and wt vTR are able to interact with TERT (blue) and
mediate telomerase activity, which is crucial for the survival of early MDV-transformed cells during initial crisis. P6.1mut vTR (Rose) is not able to
interact with TERT and can, therefore, not contribute to telomerase activity. P6.1mut, as well as wt vTR, is able to interact with RPL22 (Red) and
potentially also other factors (green) which mainly contributes to transformation and tumor dissemination.
doi:10.1371/journal.ppat.1001073.g007
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NanoDrop 1000 (Thermo Scientific).
In vitro translation of chTERT
In vitro transcribed chTERT-His or RPL22-His RNA was used
for in vitro translation using the Rabbit Reticulocyte Lysate System
(Promega) according to the manufacturer’s protocol. chTERT-His
and RPL22-His expression was analyzed by western blotting,
using a mouse anti-5xHis antibody (Qiagen).
TRAP assay
In vitro-transcribed vTR variants (1 mg) were incubated with
1 mLo fin vitro translated chTERT for 1 h at 30uC to reconstitute
the telomerase complex. Telomerase activity was subsequently
determined using the TRAPeze gel-based telomerase detection kit
S7700 (Chemicon) following the manufacturer’s instructions or the
CY5 gel-based TRAP assay as described by Herbert and
coworkers [28].
Biotin-RNA pull-down assay
4 mL in vitro translated RPL22-His was mixed with 3 nmol
biotin labeled vTR, vTR P6.1, chTR, EBER-1 or b-actin control
RNA and incubated in binding buffer (150 mM NaCl, 50 mM
Tris pH 7.0, 0.1% Tween20, 1 mg of tRNA, 0.5 mM DTT,
0.5 mM PMSF) containing 10 mg tRNA for 1 h at 37uC. 20 uL
EZview Strepavidin beads (Sigma) were washed with binding
buffer and added to the setup. After binding occurred for 1 h at
RT, supernatant was collected and beads washed 7 times with
binding buffer containing 1 mg tRNA. Precipitated and unbound
protein was analyzed by western blotting, using a mouse anti-
5xHis antibody (Qiagen).
RLP22 localization
5610
4 HeLa cells seeded on coverslips in 24-wells were
transfected using Lipofectamin 2000 (Invitrogen) with 200 ng
pcDNA-RPL22-mRed and 500 ng of either empty vector (pCMS-
EGFP), pCMS-vTR, pCMS-vTR P6.1, pCDNA-chTR or
pcDNA-RPL22. At 24 h after transfection, cells were examined
using an SP5 confocal microscope system (Leica). Images were
taken and RPL22 localization evaluated in at least 160 individual
cells per sample.
Statistical analysis
Significant differences in MD incidence were determined using
the Wilcoxon rank-sum test (Fig. 4C). Significant differences in
tumor distribution were determined using Chi-Square test
(Fig. 5A). Significant differences in mean tumor incidences were
determined using Student’s t test (Fig. 5B).
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Table 1. Primers used for cloning and mutagenesis.
Construct name sequence (59 R 39)
pP6.1mut for CGCAGGCCGCGGTCGGCCGGCACCCGCCATTGCCGCCGCGATC-
TCTTCGCCTCTGTCAGCCTCGTAGGGATAACAGGGTAATCGATTT
rev GCCGCATCTCCCGGGCGCCGCCGAGGCTGACAGAGGCGAAGAG-
ATCGCGGCGGCAATGGCGGGGCCAGTGTTACAACCAATTAACC
pP6.1rev for GCAGGCCGCGGTCGGCCGGCACCCGCCATTGCCGCCGCGAAGAG-
TTCGCCTCTGTCAGCCTCGTAGGGATAACAGGGTAATCGATTT
rev CCGCATCTCCCGGGCGCCGCCGAGGCTGACAGAGGCGAACTCTT-
CGCGGCGGCAATGGCGGGGCCAGTGTTACAACCAATTAACC
pUC119-vTR for CATGCCTGCAGTAATACGACTCACTATAGGGACACGTGGCGGGTGGAAGG
rev GATCCTCTAGATGCGCATGTGGGAGCGACGCC
pCMS-vTR for CTCGAGAATTCTGCAGATCCTCGGACACGTGGCGGGTGGAAG
rev CTAGTGGATCCCCCGGGCTGCAGGCGTGTGGGAGCGACGC
pUC119-vTR-P6.1 and pCMS-vTR-P6.1 for TCTTCGCCTCTGTCAGCCTCG
rev GATCGCGGCGGCAATGGC
puc119-vTR-AU5 for TATAACGGAGGTATTGATGGTACTGTC
rev TATATAACACAGCGGAGCCTTCCAC
pcDNA-chTERT-His for ACGCGTGGCGGGTGGAAG
rev GCGTGTGGGAGCGACGCC
pcDNA-chTR for ACGCGTGGCGGGTGGAAG
rev GCGTGTGGGAGCGACGCC
pcDNA-RPL22 for GCCGCCATGGCGCCCGT
rev GTCCTCCTCCTCCTCCTCCTCC
pcDNA-RPL22-mRFP for TAGATCTCGAGTATGGCCTCCTCCGAGGAC
rev TCAGTCTCGAGTTACAAGGCGCCGGTGG
Underlined sequences indicate restriction enzyme sites. Bold indicates mutated sequences.
doi:10.1371/journal.ppat.1001073.t001
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